Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses

Antibody based immune-checkpoint blockade therapy is a major breakthrough in oncology, leading to clinical benefit for cancer patients. Among the growing family of inhibitory receptors, the B and T lymphocyte attenuator (BTLA), which interacts with herpes virus entry mediator (HVEM), is a promising...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS One
Päätekijät: Spodzieja, Marta, Lach, Sławomir, Iwaszkiewicz, Justyna, Cesson, Valérie, Kalejta, Katarzyna, Olive, Daniel, Michielin, Olivier, Speiser, Daniel E., Zoete, Vincent, Derré, Laurent, Rodziewicz-Motowidło, Sylwia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2017
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464627/
https://ncbi.nlm.nih.gov/pubmed/28594868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0179201
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia